AR094877A1 - Anticuerpos que se unen a il-23 - Google Patents
Anticuerpos que se unen a il-23Info
- Publication number
- AR094877A1 AR094877A1 ARP140100582A ARP140100582A AR094877A1 AR 094877 A1 AR094877 A1 AR 094877A1 AR P140100582 A ARP140100582 A AR P140100582A AR P140100582 A ARP140100582 A AR P140100582A AR 094877 A1 AR094877 A1 AR 094877A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- useful
- treatment
- antibodies
- join
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente se refiere a un anticuerpo que se une a la subunidad p19 de IL-23 humana y se caracteriza por tener alta afinidad, propiedades selectivas y neutralizantes. El anticuerpo es útil en el tratamiento de prevención de una condición autoinmune o inflamatoria se selecciona a partir del grupo que consiste de esclerosis múltiple, artritis reumatoide, psoriasis, enfermedades inflamatorias del intestino, espondilitis anquilosante, enfermedad de injerto contra hospedero, lupus y síndrome metabólico. El anticuerpo es también útil en al tratamiento de cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361774732P | 2013-03-08 | 2013-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094877A1 true AR094877A1 (es) | 2015-09-02 |
Family
ID=51488096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100582A AR094877A1 (es) | 2013-03-08 | 2014-02-25 | Anticuerpos que se unen a il-23 |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US9023358B2 (es) |
| EP (3) | EP4311558A3 (es) |
| JP (1) | JP6096938B2 (es) |
| KR (2) | KR101775115B1 (es) |
| CN (1) | CN105307681B (es) |
| AP (1) | AP2015008708A0 (es) |
| AR (1) | AR094877A1 (es) |
| AU (1) | AU2014226094C1 (es) |
| BR (1) | BR112015019611B1 (es) |
| CA (1) | CA2901462C (es) |
| CL (1) | CL2015002388A1 (es) |
| CY (2) | CY1123589T1 (es) |
| DK (1) | DK2964258T3 (es) |
| EA (1) | EA031524B1 (es) |
| EC (1) | ECSP15038626A (es) |
| ES (1) | ES2822662T3 (es) |
| FI (1) | FIC20230030I1 (es) |
| FR (1) | FR23C1036I2 (es) |
| HR (1) | HRP20201633T1 (es) |
| HU (2) | HUE051357T2 (es) |
| IL (2) | IL240731B (es) |
| JO (1) | JOP20140049B1 (es) |
| LT (2) | LT2964258T (es) |
| MA (1) | MA38382A1 (es) |
| MX (1) | MX370396B (es) |
| MY (1) | MY171226A (es) |
| NL (1) | NL301247I2 (es) |
| NO (1) | NO2023037I1 (es) |
| PE (1) | PE20151529A1 (es) |
| PH (1) | PH12015501994B1 (es) |
| PL (1) | PL2964258T3 (es) |
| PT (1) | PT2964258T (es) |
| RS (1) | RS60928B1 (es) |
| SG (1) | SG11201507176VA (es) |
| SI (1) | SI2964258T1 (es) |
| TN (1) | TN2015000348A1 (es) |
| TW (1) | TWI636063B (es) |
| UA (1) | UA123198C2 (es) |
| WO (1) | WO2014137962A1 (es) |
| ZA (1) | ZA201505285B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR102417A1 (es) * | 2014-11-05 | 2017-03-01 | Lilly Co Eli | Anticuerpos biespecíficos anti-tnf- / anti-il-23 |
| MX2018005135A (es) * | 2015-10-30 | 2018-06-06 | Lilly Co Eli | Anticuerpos biespecificos anti-cgrp/anti-il-23 y usos de los mismos. |
| AR111845A1 (es) | 2017-05-03 | 2019-08-28 | Lilly Co Eli | Anticuerpos biespecíficos anti-cgrp / anti-il-23 y usos de los mismos |
| TWI837532B (zh) | 2018-03-30 | 2024-04-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
| TWI808397B (zh) | 2018-09-11 | 2023-07-11 | 美商美國禮來大藥廠 | 治療牛皮癬之方法 |
| TWI850365B (zh) | 2019-04-22 | 2024-08-01 | 美商美國禮來大藥廠 | 治療克隆氏症(crohn's disease)的方法 |
| JP7551744B2 (ja) | 2019-10-15 | 2024-09-17 | イーライ リリー アンド カンパニー | 組換え操作された、リパーゼ／エステラーゼ欠損哺乳動物細胞株 |
| CN115135671A (zh) | 2019-12-20 | 2022-09-30 | 新石生物制药有限公司 | 抗白介素-23 p19的抗体及其使用方法 |
| CN111718414B (zh) * | 2020-06-12 | 2021-03-02 | 江苏荃信生物医药有限公司 | 抗人白介素23单克隆抗体及其应用 |
| WO2022041390A1 (zh) * | 2020-08-28 | 2022-03-03 | 江苏荃信生物医药股份有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法 |
| AR123477A1 (es) | 2020-09-10 | 2022-12-07 | Lilly Co Eli | Formulaciones de anticuerpos terapéuticos |
| JP2024521748A (ja) | 2021-05-28 | 2024-06-04 | イーライ リリー アンド カンパニー | 潰瘍性大腸炎に関与する遺伝子の抗ｉｌ－２３ｐ１９抗体調節 |
| CN113698480B (zh) * | 2021-09-18 | 2022-07-01 | 东大生物技术(苏州)有限公司 | 一组il-23单克隆抗体及其医药用途 |
| WO2023056417A1 (en) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
| WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
| KR20250152080A (ko) | 2023-02-22 | 2025-10-22 | 일라이 릴리 앤드 캄파니 | 궤양성 결장염에서의 유전자의 조절 및 그의 용도 |
| JP2025537966A (ja) | 2023-03-10 | 2025-11-20 | イーライ リリー アンド カンパニー | 潰瘍性大腸炎を治療する方法 |
| WO2025083549A1 (en) | 2023-10-16 | 2025-04-24 | Sun Pharma Advanced Research Company Limited | Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders |
| US20250228864A1 (en) | 2023-11-29 | 2025-07-17 | Gilead Sciences, Inc. | Therapies for the treatment of inflammatory bowel disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
| US7422743B2 (en) | 2000-05-10 | 2008-09-09 | Schering Corporation | Mammalian receptor protein DCRS5;methods of treatment |
| TWI439285B (zh) | 2003-03-10 | 2014-06-01 | Merck Sharp & Dohme | Ｉｌ－２３激動劑及拮抗劑之用途及相關試劑 |
| US8003108B2 (en) * | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| PT1896073E (pt) * | 2005-06-30 | 2013-05-28 | Janssen Biotech Inc | Composições, métodos e aplicações de anticorpos anti-il-23 |
| CN101248088A (zh) * | 2005-08-25 | 2008-08-20 | 伊莱利利公司 | 抗il-23抗体 |
| ES2347690T3 (es) * | 2005-08-25 | 2010-11-03 | Eli Lilly And Company | Anticuerpos anti-il-23. |
| ME02705B (me) * | 2005-08-31 | 2017-10-20 | Merck Sharp & Dohme | Inženjerisana anti-il-23 antitela |
| PT2548577T (pt) * | 2005-12-29 | 2017-05-29 | Janssen Biotech Inc | Anticorpos humanos anti-il-23, composições, métodos e usos |
| CN101663320A (zh) * | 2007-02-23 | 2010-03-03 | 先灵公司 | 工程改造的抗IL-23p19抗体 |
| SI2426144T1 (sl) * | 2007-02-23 | 2019-02-28 | Merck Sharp & Dohme Corp. | Umetno proizvedena anti-IL23P19 antitelesa |
| CN101646457B (zh) * | 2007-03-20 | 2013-05-01 | 伊莱利利公司 | 抗硬骨素抗体 |
| AU2008251608B2 (en) | 2007-05-08 | 2014-03-27 | Genentech, Inc. | Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| WO2010142534A1 (en) * | 2009-05-27 | 2010-12-16 | Ablynx Nv | Biparatopic protein constructs directed against il-23 |
| PE20141162A1 (es) * | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| MX2013013054A (es) | 2011-05-12 | 2014-02-20 | Genentech Inc | Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura. |
-
2014
- 2014-02-25 AR ARP140100582A patent/AR094877A1/es active IP Right Grant
- 2014-02-25 JO JOP/2014/0049A patent/JOP20140049B1/ar active
- 2014-02-25 TW TW103106335A patent/TWI636063B/zh active
- 2014-03-04 HU HUE14761062A patent/HUE051357T2/hu unknown
- 2014-03-04 CA CA2901462A patent/CA2901462C/en active Active
- 2014-03-04 PE PE2015001903A patent/PE20151529A1/es active IP Right Grant
- 2014-03-04 PL PL14761062T patent/PL2964258T3/pl unknown
- 2014-03-04 UA UAA201508670A patent/UA123198C2/uk unknown
- 2014-03-04 EA EA201591368A patent/EA031524B1/ru not_active IP Right Cessation
- 2014-03-04 MY MYPI2015702927A patent/MY171226A/en unknown
- 2014-03-04 AU AU2014226094A patent/AU2014226094C1/en active Active
- 2014-03-04 RS RS20201236A patent/RS60928B1/sr unknown
- 2014-03-04 AP AP2015008708A patent/AP2015008708A0/xx unknown
- 2014-03-04 EP EP23207282.7A patent/EP4311558A3/en active Pending
- 2014-03-04 US US14/195,889 patent/US9023358B2/en active Active
- 2014-03-04 KR KR1020157024032A patent/KR101775115B1/ko active Active
- 2014-03-04 KR KR1020177024414A patent/KR20170103037A/ko not_active Ceased
- 2014-03-04 WO PCT/US2014/020064 patent/WO2014137962A1/en not_active Ceased
- 2014-03-04 EP EP14761062.0A patent/EP2964258B1/en active Active
- 2014-03-04 HR HRP20201633TT patent/HRP20201633T1/hr unknown
- 2014-03-04 LT LTEP14761062.0T patent/LT2964258T/lt unknown
- 2014-03-04 ES ES14761062T patent/ES2822662T3/es active Active
- 2014-03-04 PT PT147610620T patent/PT2964258T/pt unknown
- 2014-03-04 EP EP20193400.7A patent/EP3789037A1/en not_active Withdrawn
- 2014-03-04 DK DK14761062.0T patent/DK2964258T3/da active
- 2014-03-04 BR BR112015019611-0A patent/BR112015019611B1/pt active IP Right Grant
- 2014-03-04 MX MX2015011959A patent/MX370396B/es active IP Right Grant
- 2014-03-04 SG SG11201507176VA patent/SG11201507176VA/en unknown
- 2014-03-04 PH PH1/2015/501994A patent/PH12015501994B1/en unknown
- 2014-03-04 MA MA38382A patent/MA38382A1/fr unknown
- 2014-03-04 SI SI201431653T patent/SI2964258T1/sl unknown
- 2014-03-04 JP JP2015561515A patent/JP6096938B2/ja active Active
- 2014-03-04 CN CN201480012747.7A patent/CN105307681B/zh active Active
-
2015
- 2015-05-01 US US14/702,124 patent/US9688753B2/en active Active
- 2015-07-22 ZA ZA2015/05285A patent/ZA201505285B/en unknown
- 2015-08-12 TN TN2015000348A patent/TN2015000348A1/en unknown
- 2015-08-20 IL IL240731A patent/IL240731B/en active IP Right Grant
- 2015-08-26 CL CL2015002388A patent/CL2015002388A1/es unknown
- 2015-09-08 EC ECIEPI201538626A patent/ECSP15038626A/es unknown
-
2017
- 2017-06-01 US US15/611,008 patent/US20170275356A1/en not_active Abandoned
-
2020
- 2020-01-14 IL IL272042A patent/IL272042B/en unknown
- 2020-11-16 CY CY20201101081T patent/CY1123589T1/el unknown
-
2023
- 2023-10-03 FI FIC20230030C patent/FIC20230030I1/fi unknown
- 2023-10-04 NO NO2023037C patent/NO2023037I1/no unknown
- 2023-10-06 CY CY2023021C patent/CY2023021I2/el unknown
- 2023-10-06 NL NL301247C patent/NL301247I2/nl unknown
- 2023-10-13 FR FR23C1036C patent/FR23C1036I2/fr active Active
- 2023-10-18 HU HUS2300036C patent/HUS2300036I1/hu unknown
- 2023-10-23 LT LTPA2023530C patent/LTC2964258I2/lt unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094877A1 (es) | Anticuerpos que se unen a il-23 | |
| MX2016008472A (es) | Anticuero monoclonal neutralizador de anti-il-33-humana. | |
| CL2012000524A1 (es) | Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. | |
| CU24597B1 (es) | Anticuerpos biespecíficos heterodiméricos que se unen a cd3 y cd20 | |
| MX351349B (es) | Proteinas de union a antigeno. | |
| PH12019500946A1 (en) | Neutralizing anti-tl1a monoclonal antibodies | |
| MX2016012479A (es) | Miembros de unión al factor de necrosis tumoral (tnf) alfa. | |
| CL2017001154A1 (es) | Moléculas de unión específicas para cd73 y usos de las mismas | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| EA201790377A1 (ru) | Антитела к глюкагону и их применения | |
| MX382284B (es) | Anticuerpo que se une a fcrn para usarse en el tratamiento de enfermedades autoinmunes. | |
| PE20170704A1 (es) | Agente terapeutico que induce citotoxicidad | |
| CO7160039A2 (es) | Anticuerpos anti-baff-antiil-17 biespecíficos | |
| MX2022015250A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
| EA201590412A1 (ru) | Композиции антител и их применения | |
| CL2016000438A1 (es) | Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica | |
| AR094960A1 (es) | Anticuerpos de quimiocina pan-elr⁺ cxc | |
| MX2017010037A (es) | Metodos de tratamiento de enfermedades inflamatorias. | |
| NI201200144A (es) | Anticuerpos humanizados de il - 25 | |
| CR20180087A (es) | Inmunoconjugados de il22 | |
| JP2017532332A5 (es) | ||
| EA201691828A1 (ru) | Прозрачное экструдированное туалетное мыло | |
| BR112015027388A2 (pt) | Anticorpo monoclonal ou porção do mesmo que se liga a cxcr5, seu método de produção e seu uso, polinucleotídeos, vetores de expressão, célula hospedeira, e composição farmacêutica | |
| MX2021002647A (es) | Metodos de tratamiento de la psoriasis. | |
| CU20200015A7 (es) | Composición farmacéutica y kit que comprenden anticuerpos anti-tnf alpha |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |